An interventional study of omega 3 ethyl esters at 90% and Placebo in Hypertension and Dyslipidemia, sponsored by Santa Maria de la Salud, Argentina. Completed at 1 site in Argentina. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-21.
Sponsored by Santa Maria de la Salud, Argentina · Not applicable, Interventional, and Treatment
This study aims to evaluate the impact of omega-3 (O3) supplementation in participants with high blood pressure and elevated triglycerides, focusing on cardiovascular risk factors. The research is particularly relevant, as O3 has been previously validated for its effects on abnormal lipid levels. The primary and secondary objectives aim to explore the effects of O3, as well as its potential therapeutic benefits in preventing cardiovascular diseases.
The main goal of this research is to investigate how O3 supplementation influences several key cardiovascular risk markers and overall vascular health. Specifically, the study will assess and analyze changes in cholesterol levels, triglycerides, uric acid, and blood glucose levels. Since inflammation plays a major role in heart disease, the study will examine how O3 affects inflammatory markers, including ferritin, high-sensitivity C-reactive protein (hsPCR), and the neutrophil-to-leukocyte ratio. These indicators help determine the level of systemic inflammation in the body. The study also aims to measure whether O3 supplementation improves vascular elasticity.
Apart from the primary cardiovascular effects, the study also aims to determine the tolerance levels of participants receiving O3 supplementation based on their cardiovascular profiles.
The study is based on the hypothesis that taking 2 grams of O3 daily for 12 weeks will lead to a significant reduction in triglyceride levels, lower inflammation markers, improved metabolic risk factors, and enhanced arterial elasticity, which can prevent or slow the progression of cardiovascular diseases. This hypothesis is supported by growing scientific evidence that suggests O3 fatty acids, particularly long-chain polyunsaturated fatty acids (DHA and EPA), have strong cardioprotective properties.
This is a clinical study that is planned in a prospective, interventional, randomized, placebo-controlled, and double-blind format. This means that participants will be randomly assigned to either the treatment group or the placebo group, and neither the participants nor the researchers will know who is receiving the actual treatment until the study ends.
This study is a pilot study, meaning it is a small-scale preliminary study designed to test the hypothesis before conducting a larger trial.
A total of 100 participants will be recruited. Participants will be randomly assigned into two groups: O3 group, receives omega-3 (O3) treatment; and control group, receives a placebo. The assignment will be 1:1 randomization, meaning each participant has an equal (50%) chance of receiving either the treatment or the placebo. The number of participants was chosen based on estimates that a 10% reduction in blood pressure measurements (mean arterial, brachial systolic, brachial diastolic, or central systolic) would be a meaningful outcome.
The duration of omega-3 intervention is based on previous research.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 100 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →This is the only study on the registry with Santa Maria de la Salud, Argentina as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Diagnosis of hypertriglyceridemia defined as mild 150-199 mg/ moderate 200-499 mg and severe more than 500 mg.
Diagnosis of controlled arterial hypertension (BP ≤140/90 mm Hg) with stable pharmacological treatment (definitions of the Argentine Consensus on HTA, 2018).
Women of childbearing age will be included only if they are under contraceptive treatment, adopted prior to the invitation to participate in the study (hormonal contraceptives (oral, injectable, implantable, etc., intrauterine devices).
Exclusion Criteria:
2 grams/day of omega 3 capsules will be administered orally with food to optimize tolerance. (2 capsules). OMECAP 90 will be used (Registered trademark and approved by ANMAT). The capsules are provided free of charge by the manufacturer. It is recommended not to take on an empty stomach to improve tolerance. It comes in the form of capsules containing 1000 mg of omega 3 ethyl esters at 90%, gelatin 260 mg, glycerin 151 mg and purified water 39 mg.
Dietary Supplement: omega 3 ethyl esters at 90%
Mygliol 812 will be used, a mixture of various medium chain fatty acids (6 to 12 carbon atoms) that are present in various vegetable oils and do not have significant adverse effects. A capsule with the same characteristics as the O3 capsule will be administered and the same administration will be carried out.
Dietary Supplement: Placebo
2 grams/day of omega 3 capsules will be administered orally, for 12 weeks
Mygliol 812
Mean change in office systolic blood pressure from baseline
Mean change in office Systolic blood pressure from baseline in Millimeter Mercury, it measures average changes in office systolic blood pressure. Blood pressure is assessed using standardized methods while the participant is seated and resting. The measurement is taken using a validated electronic BP monitor.
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in office diastolic blood pressure from baseline
Mean change in office Diastolic blood pressure from baseline in Millimeter Mercury, it measures average changes in office diastolic blood pressure. Blood pressure is assessed using standardized methods while the participant is seated and resting. The measurement is taken using a validated electronic BP monitor.
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in 24h and Daytime Ambulatory Systolic Arterial Blood Pressure from baseline
Mean change in 24h and Daytime Ambulatory Systolic blood pressure from baseline in Millimeter Mercury, it measures average changes in systolic blood pressure. Blood pressure is assessed using standardized methods for 24 hour ambulatory measurement using a validated BP device monitor.
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in 24h and Daytime Ambulatory Diastolic Arterial Blood Pressure from baseline
Mean change in 24h and Daytime Ambulatory Diastolic blood pressure from baseline in Millimeter Mercury, it measures average changes in diastolic blood pressure. Blood pressure is assessed using standardized methods for 24 hour ambulatory measurement using a validated BP device monitor.
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in resting pulse wave velocity from baseline
Measurement of pulse wave velocity (PWV) in meters per second. The calibrated and validated Mobil-O-Graph® portable monitor (IEM GmbH, Stolberg, Germany) will be used. This module is connected to a computer to record the brachial pulse wave. It performs pulse wave analysis based on the oscillometric method. The arterial pulsation generates pressure oscillations, which are transmitted to the blood pressure cuff and measured by the transducer to be interpreted by a specific software, recording the pulse wave of the brachial artery and deriving a pulse wave from the aortic arch. All measurements will be performed on the left arm of the participant, at rest. Subjects will be instructed to be with empty bladder, not to drink coffee 60 minutes before gauging and alcoholic beverage in the last 24 hours.
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in total cholesterol from baseline
Mean change in cholesterol in Milligram/deciliter from baseline, it measures average changes in cholesterol.
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in high density lipoprotein from baseline
Mean change in high density lipoprotein (HDL) in Milligram/deciliter from baseline, it measures average changes in (HDL) cholesterol.
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in triglycerides from baseline
Mean change in triglycerides in Milligram/deciliter from baseline, it measures average changes in plasma triglycerides.
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in fasting blood sugar from baseline
Mean change in fasting blood sugar in Milligram/deciliter from baseline, it measures average changes in fasting blood sugar.
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in high sensitive C reactive protein from baseline
Mean change in high sensitive C reactive protein (Hs-CRP) in Milligram/liter, it measures average changes in high sensitive C reactive protein (Hs-CRP).
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in serum aspartate aminotransferase/serum glutamic-oxaloacetic transaminase from baseline
Serum aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT) in units per liter (U/L).
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in serum alanine transaminase/Serum Glutamic Pyruvic Transaminase from baseline
Serum alanine transaminase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) in units per liter (U/L).
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in fasting plasma insulin from baseline
Fasting plasma insulin after fasting for 8-12 hours. Results are reported in micro International Units per milliliter (uIU/mL)
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in serum ferritin from baseline
Serum ferritin is measured in nanograms per milliliter (ng/mL)
Time frame: From enrollment to the end of treatment at 12 weeks
Mean change in neutrophil-to-lymphocyte ratio from baseline
The neutrophil-to-lymphocyte ratio (NLR) is a measurement of the number of neutrophils compared to the number of lymphocytes in a blood sample. It's calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. An automated cell counter with mixed technologies performs the calculation.
Time frame: From enrollment to the end of treatment at 12 weeks
Tolerability and safety
Presence or not, described by participants, of any of the known side effects , such as belching, indigestion, and diarrhea; or symptoms such as rash, itching, swelling, severe dizziness, or trouble breathing
Time frame: From enrollment to the end of treatment at 12 weeks
Plan to share: Yes — All collected IPD will be shared with the applicant, along with a letter outlining the intended use of the data, which will be submitted to the research board for approval.
Supporting information: Study protocol, Sap, Icf, Csr, Analytic code
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.